// Company Overview //
| Stock Name | 泰德医药 |
|---|---|
| Stock Code | 03880 |
| Company Full Name | 泰德医药 |
| Industry | 醫療保健 |
| Principal Activities | 公司主要提供(i)CRO服務，即多肽NCE發現合成；及(ii)CDMO服務，即多肽CMC開發以及商業化生產。 |
| Listing Date | 2025-06-30 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | No data |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國浙江省杭州市錢塘區12號大街69號 |
| Business Address (Hong Kong) | No data |
| Place of Incorporation | No data |
| Listing Method | No data |
| Listing Board | Main Board |
| Website | https://www.medtideinc.com/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
// Offering Information //
| Offering Mechanism | 机制A(旧) |
|---|---|
| Clawback Tiers | 因超购301.1倍，回拨至50.0% |
| Offer Period | 2025-06-20 to 2025-06-25 |
| Offer Price | HK$ 30.60 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 100 shares |
| Entry Threshold | HK$ 3,060 |
| Par Value | No data |
| Global Offering Shares | 16,800,000 |
| HK Public Offering Shares | 8,400,000 (50.0%) |
| International Placing Shares | 8,400,000 (50.0%) |
| Offer Ratio | No data |
| Total Shares Post-IPO | No data |
| Total Global Offering Size | HK$ 514,080,000 |
| Public Offering Size | HK$ 257,040,000 (50.0%) |
| Oversubscription Multiple | 301.1x |
| Valid Applications | 70,338 |
| Accepted Applications | — |
| Reallocation | No |
| Total Funds Raised | HK$ 257,040,000 |
| Greenshoe (Over-allotment Option) | No |
| Final Public Offering Share | 50.0% |
// Valuation & Financials //
| Market Cap (at Offer Price) | HK$ 0 |
|---|---|
| Pre-IPO Valuation (Last Round) | No data |
| P/E Ratio | 68.75 |
| Profit/Loss Status | No data |
| Period-End Cash Balance | No data |
| Listing Expenses | ~HK$ 85,310,000 |
| Listing Expenses / Funds Raised | No data |
| Total Pre-IPO Investment | No data |
// First Day Performance
| First Day Close | Loading... |
|---|---|
| First Day Open | HK$ 30.3 |
| First Day Change | 0.65% |
| First Day Volume | 8593800.0 |
| First Day Turnover | 272301000.0 |
// Price Chart //
Loading...
// Use of Proceeds
| Use of Proceeds | 1、約76.4%（或314.0百萬港元）將用于在美國及中國建設設施以進一步擴大公司服務能力及產能； 2、約4.1%（或16.9百萬港元）將用于擴張中國的產能； 3、約9.5%（或39.2百萬港元）將用于在更多地區建立銷售及售后服務網點，以豐富公司全球業務及擴大公司客戶群； 4、約10.0%（或41.1百萬港元）將用于公司營運資金及其他一般公司用途。 |
|---|
// Underwriting Syndicate //
联席保荐人 (2)
摩根士丹利亚洲有限公司
中信证券（香港）有限公司
整体协调人 (2)
摩根士丹利亚洲有限公司
中信里昂证券有限公司
联席账簿管理人 (5)
摩根士丹利亚洲有限公司
中信里昂证券有限公司
中国光大证券（香港）有限公司
发利证券有限公司
东吴证券国际经纪有限公司
联席牵头经办人 (6)
摩根士丹利亚洲有限公司
中信里昂证券有限公司
中国光大证券（香港）有限公司
发利证券有限公司
东吴证券国际经纪有限公司
雅利多证券有限公司
// Cornerstone Investors //
Allotment Results Announcement
| # | Investor Name | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|
| 1 | 蘭溪普華碩陽夏星創業 | 9,131,875 | 12.41% | 6.44% | 2026-06-29 | 2026-06-29 |
| 2 | 衢州海邦肽達創業投資 | 7,209,375 | 9.80% | 5.08% | 2026-06-29 | 2026-06-29 |
| 3 | 深圳市民和投資有限公 | 2,739,625 | 3.72% | 1.93% | 2026-06-29 | 2026-06-29 |
| 4 | 杭州海邦博源創業投資 | 2,283,000 | 3.10% | 1.61% | 2026-06-29 | 2026-06-29 |
| 5 | 海南景盛一期私募股權 | 1,369,750 | 1.86% | 0.97% | 2026-06-29 | 2026-06-29 |
| 6 | 南京歐陶信息科技有限 | 1,369,750 | 1.86% | 0.97% | 2026-06-29 | 2026-06-29 |
| 7 | 佳曦控股有限公司 | 1,282,500 | 7.63% | 0.90% | 2025-12-29 | 2025-12-29 |
| 8 | Welight Capital L.P. | 1,282,500 | 7.63% | 0.90% | — | — |
| 9 | WelightCapitalL.P. | 1,282,500 | 1.74% | 0.90% | 2025-12-29 | 2025-12-29 |
// Directors & Management //
| Chairman | 徐琪 |
|---|---|
| Company Secretary | 李玲梅,吳東澄 |
No director data available.
// Major Shareholders //
| Major Shareholders & Holdings | 琪康國際有限公司(42.01%),杭州海鼎科技有限公司(10.87%),李湘莉(7.24%),衢州海邦肽達創業投資合伙企業(有限合伙)及杭州海邦博源創業投資合伙企業(有限合伙)(6.69%) |
|---|
// Allotment Benchmarks //
Pool A (Small Subscriptions)
| Shares Applied | Applicants | Allottees | Expected Lots |
|---|---|---|---|
| 100 | 24,499 | 12,250 | 0.50 |
| 200 | 5,895 | 3,006 | 0.51 |
| 300 | 5,426 | 2,784 | 0.51 |
| 400 | 2,251 | 1,156 | 0.51 |
| 500 | 2,807 | 1,443 | 0.51 |
| 600 | 1,423 | 732 | 0.51 |
| 700 | 929 | 479 | 0.52 |
| 800 | 908 | 469 | 0.52 |
| 900 | 452 | 234 | 0.52 |
| 1,000 | 5,390 | 2,796 | 0.52 |
| 1,500 | 2,057 | 1,070 | 0.52 |
| 2,000 | 2,054 | 1,073 | 0.52 |
| 2,500 | 799 | 419 | 0.53 |
| 3,000 | 1,628 | 859 | 0.53 |
| 3,500 | 1,026 | 545 | 0.53 |
| 4,000 | 798 | 427 | 0.54 |
| 4,500 | 442 | 238 | 0.54 |
| 5,000 | 1,468 | 798 | 0.55 |
| 6,000 | 816 | 448 | 0.55 |
| 7,000 | 732 | 410 | 0.56 |
| 8,000 | 614 | 354 | 0.58 |
| 9,000 | 342 | 200 | 0.59 |
| 10,000 | 2,730 | 1,643 | 0.60 |
| 20,000 | 1,208 | 1,208 | 1.00 |
| 30,000 | 725 | 276 | 1.38 |
| 40,000 | 497 | 318 | 1.64 |
| 50,000 | 453 | 453 | 2.00 |
| 60,000 | 242 | 82 | 2.34 |
| 70,000 | 219 | 145 | 2.66 |
| 80,000 | 190 | 190 | 3.04 |
| 90,000 | 102 | 15 | 3.15 |
| 100,000 | 349 | 140 | 3.40 |
| 150,000 | 202 | 202 | 4.95 |
Pool B (Large Subscriptions)
| Shares Applied | Applicants | Allottees | Expected Lots |
|---|---|---|---|
| 200,000 | 383 | 383 | 44.00 |
| 250,000 | 39 | 39 | 53.00 |
| 300,000 | 54 | 54 | 62.10 |
| 350,000 | 40 | 40 | 71.05 |
| 400,000 | 22 | 22 | 79.20 |
| 450,000 | 15 | 15 | 85.95 |
| 500,000 | 35 | 35 | 94.00 |
| 600,000 | 24 | 24 | 112.20 |
| 700,000 | 11 | 11 | 128.80 |
| 840,000 | 42 | 42 | 153.72 |
Offer Ratio
Allotment Benchmarks
